Added to YB: 2026-06-01
Pitch date: 2026-05-28
INKT [bullish]
MiNK Therapeutics, Inc.
Author Info
Company Info
MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, manufacture, and commercialization of allogeneic, off-the-shelf, and invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases.
Market Cap
$53.4M
Pitch Price
N/A
Price Target
N/A
Dividend
N/A
EV/EBITDA
-3.42
P/E
-3.85
EV/Sales
N/A
Sector
Biotechnology
Category
growth
MiNK Therapeutics: One Cell. Every Disease. The $50M Company Hiding in Plain Sight.
INKT: Only US public co advancing off-the-shelf iNKT cell therapy. Lead asset agenT-797 shows dual mode—cytotoxic in cancer (median survival >23mo in refractory pts), restorative in ARDS. Platform potential w/ FAP-CAR & PRAME-TCR. ~$50M cap, pre-rev, no debt. Key catalyst: randomized Phase 2 lung injury readout H2 2026. Moat: manufacturing scale (~1B cells/donor), rivals (Appia, Athenex) collapsed. High dilution risk but vast asymmetry.
Read full article (13 min)